“While there have been many recent advances in the field of melanoma regarding immunotherapy, there is much more is to come, says Antoni Ribas, MD, PhD.
“One notable breakthrough, which demonstrates the significant potential of the field, is the phase II CheckMate-069 trial, which examined the combination of ipilimumab (Yervoy) and nivolumab (Opdivo). The combination showed a 42% improvement in overall survival (OS) when compared with ipilimumab as a monotherapy.
“In an interview with Targeted Oncology, Ribas, a professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, discusses what these data mean and where the field of immunotherapy in melanoma is headed.”
Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.